

Amendments to the Claims

Listing of Claims

1-14 (canceled)

15. (currently amended): A liquid-droplet aerosol composition for delivery to a patient's respiratory tract

(a) formed by placing an aqueous γ -IFN solution having a known, selected γ -IFN biological activity, and ~~containing~~ comprising a stabilizing agent consisting of sugar, alcohol, amino acid, or a combination thereof, and a dispersing agent, against a plate having defined-sized openings, and forcing the solution through said openings, under conditions effective to form aqueous droplets having (a)' a narrow distribution of sizes that is less than 2 standard deviations from the volume mean diameter of the droplets, wherein the a-volume mean diameter is in a selected size range selected from the group consisting of (i) less than 1 micron, (ii) 1-3 microns, (iii) 3-5 microns, (iv) 5-10 microns, (v) greater than 10 microns, and (vi) two or more of the size ranges, (b)' a γ -IFN biological activity substantially the same as that of the solution, and (c)' a γ -IFN molecular size distribution substantially the same as that of the solution; and

(b) characterized by an aerosol of aqueous droplets having (a)' a narrow distribution of sizes that is less than 2 standard deviations from the volume mean diameter of the droplets, wherein the [a] volume mean diameter is in a selected size range selected from the group and consisting of (i) less than 1 micron, (ii) 1-3 microns, (iii) 3-5 microns, (iv) 5-10 microns, (v) greater than 10 microns, ~~(vi) two or more of the size ranges,~~ (b)' a γ -IFN biological activity substantially the same as that of the solution, and (c)' a γ -IFN molecular size distribution substantially the same as that of the solution.

16 (original): The composition of claim 15, wherein said solution contain at least one million International units of gamma-IFN/ml, as measured by (i) the ability of γ -IFN to stimulate CD64 antigen expression in cultured enriched human monocytes, or (ii) the biological activity

of the γ -IFN in solution and droplet form is determined by the ability of γ -IFN to stimulate HLA-DR antigen expression in cultured human monocytes.

17. (original): The composition of claim 15, wherein said solution includes mannitol as a stabilizing agent.

18. (original): The composition of claim 17, wherein said mannitol is present in an amount between 5-15 mM.

19. (original): The composition of claim 15, wherein said solution includes polysorbate as a dispersing agent.

20. (original): The composition of claim 19, wherein the polysorbate is present in an amount between 50-200 mg/liter weight percent.

21. (original): The composition of claim 15, wherein the solution has a viscosity at room temperature of less than 2Cp.

22. (new): A liquid-droplet aerosol composition for delivery to a patient's respiratory tract
(a) formed from an aqueous γ -IFN solution having a known, selected γ -IFN biological activity, and comprising a dispersing agent and a stabilizing agent consisting of sugar, alcohol, amino acid, or a combination thereof, and

(b) wherein the aqueous droplets are characterized by

(a)' a narrow particle distribution such that at least 80% of the droplets have a size in a selected size range, wherein the selected size range is selected from the group consisting of (i) less than 1 micron, (ii) 1-3 microns, (iii) 3-5 microns, (iv) 5-10 microns, and (v) greater than 10 microns, ~~and (vi) two or more of the size ranges,~~
(b)' a γ -IFN biological activity substantially the same as that of the solution; and
(c)' a γ -IFN molecular size distribution substantially the same as that of the solution.

Serial No. 09/747,383

Applicant: Van Vlasselaer et al.

Reply to Office Action of: January 13, 2003

Amendment dated: July 14, 2003

23. (new): The composition of claim 22, wherein at least 95% of the droplets have a size in
the selected size range.
